Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>=70 years of age~* Non-small cell lung cancer~* Naive to prior chemotherapy or specific immunotherapy~* Presence of at least 1 measurable lesion~Exclusion Criteria:~* Active non-controlled infection or disease~* CNS metastases~* Any other malignancies (other than adequately treated basal cell cancer of skin, or in situ cancer of the cervix)

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).